Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;36(2):217-25.
doi: 10.1080/08897077.2014.902787. Epub 2014 Apr 4.

Buprenorphine Treatment for Probationers and Parolees

Michael S Gordon  1 , Timothy W Kinlock, Robert P Schwartz, Kathryn A Couvillion, Laura J Sudec, Kevin E O'Grady, Frank J Vocci, Hamin Shabazz
Affiliations

Buprenorphine Treatment for Probationers and Parolees

Michael S Gordon et al. Subst Abus. 2015.

Abstract

Background: Pharmacotherapy studies involving buprenorphine have rarely been conducted with U.S. community corrections populations. This is one of the first reports of buprenorphine treatment outcomes of adult opioid-dependent probationers and parolees.

Methods: This longitudinal study examined the 3-month treatment outcomes for a sample of probation and parole clients (N = 64) who received community-based buprenorphine treatment.

Results: Approximately two thirds of the sample (67%) were still in treatment at 3 months post baseline. Furthermore, there was a significant decline in the number of self-reported heroin use days and crime days from baseline to 3 months post baseline. Although there was not a significant reduction in reincarcerations, there was no evidence that they had increased.

Conclusions: Given that buprenorphine is approved by the Food and Drug Administration (FDA) as a safe, effective treatment for opioid use disorders, individuals on parole or probation should have the opportunity to benefit from it through community-based programs.

Keywords: Buprenorphine treatment; opioid use; parolees; probationers.

PubMed Disclaimer

References

    1. Glaze LP, Bonczar TP. Probation and Parole in the United States. United States Department of Justice, Bureau of Justice Statistics; Washington, DC: 2010. 2011. Bulletin: NCJ 236019.
    1. Schmalleger F. Criminal Justice Today: An introductory text for the 21st century. 10th ed. Pearson Prentice Hall; Upper Saddle River, NJ: 2010.
    1. Cropsey KL, Lane PS, Hale GJ, et al. Results of a pilot randomized controlled trial of buprenorphine for opioid dependent women in the criminal justice system. Drug Alcohol Depend. 2011 Dec 15;119(3):172–178. - PMC - PubMed
    1. Lee JD, Grossman E, Truncali A, et al. Buprenorphine-naloxone maintenance following release from jail. Subst Abus. 2012;33(1):40–47. - PMC - PubMed
    1. Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009 Jan 1;99(1-3):222–230. - PMC - PubMed

Publication types